0001209191-23-018460.txt : 20230314
0001209191-23-018460.hdr.sgml : 20230314
20230314162250
ACCESSION NUMBER: 0001209191-23-018460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230310
FILED AS OF DATE: 20230314
DATE AS OF CHANGE: 20230314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WAGNER CHARLES F JR
CENTRAL INDEX KEY: 0001223348
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 23731320
MAIL ADDRESS:
STREET 1: C/O MILLIPORE CORP
CITY: BILLERICA
STATE: MA
ZIP: 01820
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-10
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001223348
WAGNER CHARLES F JR
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP & Chief Financial Officer
Common Stock
2023-03-10
4
S
0
361
286.64
D
57772
D
Common Stock
2023-03-10
4
S
0
515
287.83
D
57257
D
Common Stock
2023-03-10
4
S
0
327
288.91
D
56930
D
Common Stock
2023-03-10
4
S
0
30
289.44
D
56900
D
Common Stock
2023-03-10
4
S
0
541
291.47
D
56359
D
Common Stock
2023-03-10
4
S
0
185
292.68
D
56174
D
Common Stock
2023-03-10
4
S
0
27
293.61
D
56147
D
Common Stock
2023-03-10
4
S
0
102
294.94
D
56045
D
Common Stock
2023-03-13
4
S
0
24
288.31
D
56021
D
Common Stock
2023-03-13
4
S
0
420
292.41
D
55061
D
Common Stock
2023-03-13
4
S
0
1153
293.35
D
54448
D
Common Stock
2023-03-13
4
S
0
715
294.52
D
53733
D
Common Stock
2023-03-13
4
S
0
292
295.89
D
53441
D
Common Stock
2023-03-13
4
S
0
62
296.77
D
53379
D
Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1.
Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $286.64 (range $286.17 to $287.16).
Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.30 to $288.20).
Open market sales reported on this line occurred at a weighted average price of $288.91 (range $288.37 to $289.34).
Open market sales reported on this line occurred at a weighted average price of $291.47 (range $291.10 to $292.00).
Open market sales reported on this line occurred at a weighted average price of $292.68 (range $292.14 to $293.12).
Open market sales reported on this line occurred at a weighted average price of $294.94 (range $294.85 to $295.35).
Open market sales reported on this line occurred at a weighted average price of $292.41 (range $291.97 to $292.82).
Open market sales reported on this line occurred at a weighted average price of $293.35 (range $292.99 to $293.80).
Open market sales reported on this line occurred at a weighted average price of $294.52 (range $294.13 to $294.81).
Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.33 to $296.32).
/s/ Christiana Stevenson, Attorney-in-Fact
2023-03-14